Assessing the Optimality of a COVID Lockdown in the United States.

Anna Scherbina
{"title":"Assessing the Optimality of a COVID Lockdown in the United States.","authors":"Anna Scherbina","doi":"10.1007/s41885-021-00083-6","DOIUrl":null,"url":null,"abstract":"<p><p>Though COVID vaccines have been available since December 2020, the rate at which they are administered remains slow, and in the meantime the pandemic continues to claim about as many lives every day as the 9/11 tragedy. I estimate that with the promised rate of vaccinations, if no additional non-pharmaceutical interventions are implemented, 203 thousand additional lives will be lost and the future cost of the pandemic will reach $1.3 trillion, or 6% of GDP. Using a cost-benefit analysis, I assess whether it is optimal for the United States to follow the lead of many European countries and introduce a nation-wide lockdown. I find that a lockdown would be indeed optimal and, depending on the assumptions, it should last between two and four weeks and will generate a net benefit of up to $653 billion.</p>","PeriodicalId":72868,"journal":{"name":"Economics of disasters and climate change","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105692/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Economics of disasters and climate change","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41885-021-00083-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/5/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Though COVID vaccines have been available since December 2020, the rate at which they are administered remains slow, and in the meantime the pandemic continues to claim about as many lives every day as the 9/11 tragedy. I estimate that with the promised rate of vaccinations, if no additional non-pharmaceutical interventions are implemented, 203 thousand additional lives will be lost and the future cost of the pandemic will reach $1.3 trillion, or 6% of GDP. Using a cost-benefit analysis, I assess whether it is optimal for the United States to follow the lead of many European countries and introduce a nation-wide lockdown. I find that a lockdown would be indeed optimal and, depending on the assumptions, it should last between two and four weeks and will generate a net benefit of up to $653 billion.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估美国 COVID 封锁的最优性。
尽管 COVID 疫苗自 2020 年 12 月起就已上市,但接种速度仍然缓慢,与此同时,大流行病每天夺走的生命与 9/11 悲剧一样多。我估计,按照承诺的疫苗接种率,如果不采取额外的非药物干预措施,将有 20.3 万人丧生,大流行病的未来成本将达到 1.3 万亿美元,占国内生产总值的 6%。通过成本效益分析,我评估了美国是否应该效仿许多欧洲国家,在全国范围内实行封锁。我发现,封锁确实是最佳选择,根据不同的假设,封锁应持续两到四周,并将产生高达 6530 亿美元的净收益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Indian Agriculture Under Climate Change: The Competing Effect of Temperature and Rainfall Anomalies Valuing the Economic Impact of River Floods and Early Flood Warning for Households in Bangladesh Assessing “Invisible Loss” During Medium-Term Earthquake Recovery: The Case of Indonesia's 2016 Aceh Earthquakes Climate-related Disaster and Human Capital Investment in the Global South — Household Heterogeneity and Growth The Impacts of Multiple Tropical Cyclone Events and Associated Precipitation on Household Income and Expenditures
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1